Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4854621 | 0.83 | TDP1 (0.39) | TDP1DGAT1NFKB1NFKB2RELA | |
| SCHEMBL23863605 | 0.82 | TDP1 (0.36) | TDP1DGAT1NFKB1NFKB2RELA | |
| SCHEMBL2933102 | 0.82 | CA1 (0.39) | TDP1DGAT1NFKB1NFKB2RELA | |
| SCHEMBL101218 | 0.82 | DGAT1 (0.46) | TDP1DGAT1NFKB1NFKB2RELA | |
| SCHEMBL12583704 | 0.81 | TDP1 (0.38) | TDP1DGAT1NFKB1NFKB2RELA | |
| SCHEMBL3951511 | 0.80 | APLNR (0.41) | TDP1DGAT1NFKB1NFKB2RELA | |
| SCHEMBL3755352 | 0.80 | DGAT1 (0.41) | TDP1DGAT1NFKB1NFKB2RELA | |
| SCHEMBL6272856 | 0.79 | DGAT1 (0.44) | TDP1DGAT1NFKB1NFKB2RELA | |
| SCHEMBL1522412 | 0.79 | DGAT1 (0.44) | TDP1DGAT1NFKB1NFKB2RELA | |
| Potassium SCHEMBL29554503 | 0.79 | DGAT1 (0.44) | TDP1DGAT1NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3668867-B1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) FLT3 INHIBITORS | UNIV REGENSBURG (DE) | 2023-10-04 | — | — | EP | disclosed |
| WO-2017015496-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2017-01-26 | — | — | WO | disclosed |
| WO-2014035872-A1 | TRICYCLIC ALKYNES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN | AMGEN INC. (US) | 2014-03-06 | — | — | WO | disclosed |
| US-20120189601-A1 | ASSISTED ENZYME REPLACEMENT THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-07-26 | — | — | US | disclosed |
| US-7141567-B2 | Polysubstituted imidazopyridines as gastric secretion inhibitors | ALTANA PHARMA AG (DE) | 2006-11-28 | — | — | US | disclosed |
| US-20060035892-A1 | Nitrosated imidazopyridines | ATLANTA PHARMA AG (DE) | 2006-02-16 | — | — | US | disclosed |
| US-6869949-B2 | Polysubstituted imidazopyridines as gastric secretion inhibitors | ALTANA PHARMA AG (DE) | 2005-03-22 | — | — | US | disclosed |
| EP-1504003-A1 | NITROSATED IMIDAZOPYRIDINES | ALTANA Pharma AG (DE) | 2005-02-09 | — | — | EP | disclosed |
| US-20040214852-A1 | Polysubstituted imidazopyridines | ALTANA PHARMA AG (DE) | 2004-10-28 | — | — | US | disclosed |
| US-20040106642-A1 | POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS | ALTANA PHARMA AG (DE) | 2004-06-03 | — | — | US | disclosed |
| WO-2003091253-A1 | NITROSATED IMIDAZOPYRIDINES | ALTANA PHARMA AG (DE) | 2003-11-06 | — | — | WO | disclosed |
| EP-1332143-A1 | POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS | ALTANA Pharma AG (DE) | 2003-08-06 | — | — | EP | disclosed |
| US-6384048-B1 | GASTROINTESTINAL DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2002-05-07 | — | — | US | disclosed |
| WO-2002034749-A1 | POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS | ALTANA PHARMA AG (DE) | 2002-05-02 | — | — | WO | disclosed |
| EP-1127059-A1 | IMIDAZONAPHTHYRIDINES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000026217-A1 | IMIDAZONAPHTHYRIDINES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106642-A1 | POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS | GIPR, SLC10A2, VIP | TDP1 4704/4885DGAT1 2714/4885NFKB1 2393/4885 |
| US-20060035892-A1 | Nitrosated imidazopyridines | NOS2, NOS1, NOS3 | TDP1 2939/4885DGAT1 3688/4885NFKB1 349/4885 |
| US-20120189601-A1 | ASSISTED ENZYME REPLACEMENT THERAPY | GAA, GLA, ENPEP | TDP1 1191/4885DGAT1 438/4885NFKB1 4578/4885 |
| US-20040214852-A1 | Polysubstituted imidazopyridines | GIPR, VIP, SLC10A2 | TDP1 4530/4885DGAT1 3456/4885NFKB1 2077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.